Review of transcutaneous and intradermal vaccination

Human Vaccines

Volumn 7, Issue 8, 2011, Pages

  Combadiere, Behazine ^a   Liard, Christelle ^a  

^a INSERM   (France)

Author keywords

Immune responses; Intradermal; Skin; Transcutaneous; Vaccination

Indexed keywords

AGGRIPAL; ALPHA RIX; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; INTERLEUKIN 1; INTERLEUKIN 6; LANGERIN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; RABIES VACCINE; RANTES; TETRAGRIP; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BASEMENT MEMBRANE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG SAFETY; EPIDERMIS; FUNCTIONS OF THE SKIN AND ITS APPENDAGES; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; INFLUENZA; INNATE IMMUNITY; INTERNALIZATION; KERATINOCYTE; LANGERHANS CELL; LYMPH NODE; MACROPHAGE; MERKEL CELL; NONHUMAN; PHENOTYPE; PLASTICITY; PROTEIN BINDING; RABIES; REVIEW; SEASONAL INFLUENZA; SKIN SURFACE; T LYMPHOCYTE; VACCINATION;

EID: 80051901793     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. Streilein J.W. Skin-associated lymphoid tissues (SALT): Origins and functions. J Invest Dermatol 1983; 80 Suppl:12s-16s (Pubitemid 13063552)
2. Streilein J.W., Lonsberry L.W., Bergstresser P.R. Depletion of epidermal langerhans cells and Ia immunogenicity from tape-stripped mouse skin. J Exp Med 1982; 155:863-871 (Pubitemid 12187859)
3. Bos J.D., Kapsenberg M.L. The skin immune system: Progress in cutaneous biology. Immunol Today 1993; 14:75-78 (Pubitemid 23046167)
4. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: Mechanisms and clinical consequences. Nat Rev Immunol 2004; 4:211-222 (Pubitemid 38339087)
5. Nestle F.O., Di Meglio P., Qin J.Z., Nickoloff B.J. Skin immune sentinels in health and disease. Nat Rev Immunol 2009; 9:679-691
6. Anjuere F., Del Hoyo G.M., Martin P., Ardavin C. Langerhans cells develop from a lymphoid-committed precursor. Blood 2000; 96:1633-1637
7. Ito T., Inaba M., Inaba K., Toki J., Sogo S., Iguchi T., et al. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol 1999; 163:1409-1419 (Pubitemid 29352761)
8. Jakob T., Ring J., Udey M.C. Multistep navigation of Langerhans/dendritic cells in and out of the skin. J Allergy Clin Immunol 2001; 108:688-696 (Pubitemid 33096196)
9. Dieu-Nosjean M.C., Massacrier C., Homey B., Vanbervliet B., Pin J.J., Vicari A., et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000; 192:705-718
10. Tang A., Amagai M., Granger L.G., Stanley J.R., Udey M.C. Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. Nature 1993; 361:82-85 (Pubitemid 23020779)
11. Valladeau J., Saeland S. Cutaneous dendritic cells. Semin Immunol 2005; 17:273-283 (Pubitemid 40984021)
12. Mulholland W.J., Arbuthnott E.A., Bellhouse B.J., Cornhill J.F., Austyn J.M., Kendall M.A., et al. Multiphoton high-resolution 3D imaging of Langerhans cells and keratinocytes in the mouse skin model adopted for epidermal powdered immunization. J Invest Dermatol 2006; 126:1541-1548
13. Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29:497-510.
14. Ochoa M.T., Loncaric A., Krutzik S.R., Becker T.C., Modlin R.L. "Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. J Invest Dermatol 2008; 128:2225-2231
15. Valladeau J., Ravel O., Dezutter-Dambuyant C., Moore K., Kleijmeer M., Liu Y., et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000; 12:71-81. (Pubitemid 30069216)
16. Valladeau J., Clair-Moninot V., Dezutter-Dambuyant C., Pin J.J., Kissenpfennig A., Mattei M.G., et al. Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues. J Immunol 2002; 168:782-792 (Pubitemid 34049579)
17. McDermott R., Bausinger H., Fricker D., Spehner D., Proamer F., Lipsker D., et al. Reproduction of Langerin/CD207 traffic and Birbeck granule formation in a human cell line model. J Invest Dermatol 2004; 123:72-77 (Pubitemid 38833466)
18. Stoitzner P., Tripp C.H., Douillard P., Saeland S., Romani N. Migratory Langerhans cells in mouse lymph nodes in steady state and inflammation. J Invest Dermatol 2005; 125:116-125 (Pubitemid 40981432)
19. Kissenpfennig A., Henri S., Dubois B., Laplace-Builhe C., Perrin P., Romani N., et al. Dynamics and function of Langerhans cells in vivo: Dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005; 22:643-654 (Pubitemid 40719199)
20. Udey M.C. Langerhans cells on guard in the epidermis: Poised to dSEARCH and ...? J Invest Dermatol 2006; 126:705-707
21. Geissmann F., Dieu-Nosjean M.C., Dezutter C., Valladeau J., Kayal S., Leborgne M., et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 2002; 196:417-430
22. Clark R.A. Skin-resident T cells: The ups and downs of on site immunity. J Invest Dermatol 2010; 130:362-370
23. Nakanishi Y., Lu B., Gerard C., Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462:510-513
24. Hayday A., Tigelaar R. Immunoregulation in the tissues by gammadelta T cells. Nat Rev Immunol 2003; 3:233-242
25. Zaba L.C., Krueger J.G., Lowes M.A. Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol 2009; 129:302-308
26. Torocsik D., Bardos H., Nagy L., Adany R. Identification of factor XIII-A as a marker of alternative macrophage activation. Cell Mol Life Sci 2005; 62:2132-2139 (Pubitemid 41291669)
27. Lambert P.H., Laurent P.E. Intradermal vaccine delivery: Will new delivery systems transform vaccine administration? Vaccine 2008; 26:3197-3208
28. Udey M.C., Nagao K. Characteristics and functions of murine cutaneous dendritic cells: A synopsis of recent developments. Mucosal Immunol 2008; 1:470-474
29. Romani N., Clausen B.E., Stoitzner P. Langerhans cells and more: Langerin-expressing dendritic cell subsets in the skin. Immunol Rev 2010; 234:120-141
30. Merad M., Ginhoux F., Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008; 8:935-947
31. Clark R.A., Chong B., Mirchandani N., Brinster N.K., Yamanaka K., Dowgiert R.K., et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176:4431-4439 (Pubitemid 44264423)
32. Sigmundsdottir H., Butcher E.C. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008; 9:981-987
33. Woodland D.L., Kohlmeier J.E. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009; 9:153-161
34. Foster C.A., Yokozeki H., Rappersberger K., Koning F., Volc-Platzer B., Rieger A., et al. Human epidermal T cells predominantly belong to the lineage expressing alpha/beta T cell receptor. J Exp Med 1990; 171:997-1013. (Pubitemid 20120129)
35. Puissant-Lubrano B., Bossi P., Gay F., Crance J.M., Bonduelle O., Garin D., et al. Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+ effector/memory CD4+ lymphocytes in humans. J Clin Invest 2010; 120:1636-1644
36. Nicolas J.F., Guy B. Intradermal, epidermal and transcutaneous vaccination: From immunology to clinical practice. Expert Rev Vaccines 2008; 7:1201-1214
37. Mikszta J.A., Laurent P.E. Cutaneous delivery of prophylactic and therapeutic vaccines: Historical perspective and future outlook. Expert Rev Vaccines 2008; 7:1329-1339
38. Laurent P.E., Bonnet S., Alchas P., Regolini P., Mikszta J.A., Pettis R., et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25:8833-8842 (Pubitemid 350192056)
39. Reddy S.T., Van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007; 25:1159-1164 (Pubitemid 47538111)
40. Shklovskaya E., Roediger B., Fazekas de St Groth B. Epidermal and dermal dendritic cells display differential activation and migratory behavior while sharing the ability to stimulate CD4+ T cell proliferation in vivo. J Immunol 2008; 181:418-430
41. Ponvert C., Scheinmann P. Vaccine allergy and pseudoallergy. Eur J Dermatol 2003; 13:10-15
42. Widera G., Johnson J., Kim L., Libiran L., Nyam K., Daddona P.E., et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 2006; 24:1653-1664 (Pubitemid 43238242)
43. Donnelly R.F., Raj Singh T.R., Woolfson A.D. Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. Drug Deliv 2010; 17:187-207.
44. Harvey A.J., Kaestner S.A., Sutter D.E., Harvey N.G., Mikszta J.A., Pettis R.J. Microneedle-Based Intradermal Delivery Enables Rapid Lymphatic Uptake and Distribution of Protein Drugs. Pharm Res 2010.
45. Zhu Q., Zarnitsyn V.G., Ye L., Wen Z., Gao Y., Pan L., et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci U S A 2009; 106:7968-7973
46. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004; 56:581-587 (Pubitemid 38326934)
47. Quan F.S., Kim Y.C., Compans R.W., Prausnitz M.R., Kang S.M. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 2010; 147:326-332
48. Kaushik S., Hord A.H., Denson D.D., McAllister D.V., Smitra S., Allen M.G., et al. Lack of pain associated with microfabricated microneedles. Anesth Analg 2001; 92:502-504 (Pubitemid 32127644)
49. Liard C., Munier S., Arias M., Joulin-Giet A., Bonduelle O., Duffy D., et al. Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 2011.
50. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005; 5:905-916 (Pubitemid 41746760)
51. Kermode M. Healthcare worker safety is a pre-requisite for injection safety in developing countries. Int J Infect Dis 2004; 8:325-327 (Pubitemid 39370978)
52. Bos J.D., Meinardi M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000; 9:165-169 (Pubitemid 30255378)
53. Mikszta J.A., Alarcon J.B., Brittingham J.M., Sutter D.E., Pettis R.J., Harvey N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 2002; 8:415-419 (Pubitemid 34407039)
54. El Maghraby G.M., Williams A.C., Barry B.W. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm 2004; 276:143-161 (Pubitemid 38542995)
55. Mahe B., Vogt A., Liard C., Duffy D., Abadie V., Bonduelle O., et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009; 129:1156-1164
56. Vogt A., Combadiere B., Hadam S., Stieler K.M., Lademann J., Schaefer H., et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 2006; 126:1316-1322 (Pubitemid 43997914)
57. Vogt A., Mahe B., Costagliola D., Bonduelle O., Hadam S., Schaefer G., et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunol 2008; 180:1482-1489
58. Combadiere B., Vogt A., Mahe B., Costagliola D., Hadam S., Bonduelle O., et al. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: A randomized phase I trial. PLoS One 2010; 5:e10818.
59. Paus R., Christoph T., Muller-Rover S. Immunology of the hair follicle: A short journey into terra incognita. J Investig Dermatol Symp Proc 1999; 4:226-234 (Pubitemid 30085810)
60. Ito T., Ito N., Saatoff M., Hashizume H., Fukamizu H., Nickoloff B.J., et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol 2008; 128:1196-1206 (Pubitemid 351543218)
61. Gilliam A.C., Kremer I.B., Yoshida Y., Stevens S.R., Tootell E., Teunissen M.B., et al. The human hair follicle: A reservoir of CD40+ B7-deficient Langerhans cells that repopulate epidermis after UVB exposure. J Invest Dermatol 1998; 110:422-427 (Pubitemid 28158661)
62. Naito S., Maeyama J., Mizukami T., Takahashi M., Hamaguchi I., Yamaguchi K. Transcutaneous immunization by merely prolonging the duration of antigen presence on the skin of mice induces a potent antigen-specific antibody response even in the absence of an adjuvant. Vaccine 2007; 25:8762-8770 (Pubitemid 350192063)
63. Knorr F., Lademann J., Patzelt A., Sterry W., Blume-Peytavi U., Vogt A. Follicular transport route - research progress and future perspectives. Eur J Pharm Biopharm 2009; 71:173-180
64. Korting H.C., Braun-Falco O. The effect of detergents on skin pH and its consequences. Clin Dermatol 1996; 14:23-27 (Pubitemid 26096024)
65. Cao T., Ueno H., Glaser C., Fay J.W., Palucka A.K., Banchereau J. Both Langerhans cells and interstitial DC cross-present melanoma antigens and efficiently activate antigen-specific CTL. Eur J Immunol 2007; 37:2657-2667 (Pubitemid 47423633)
66. Nestle F.O., Filgueira L., Nickoloff B.J., Burg G. Human dermal dendritic cells process and present soluble protein antigens. J Invest Dermatol 1998; 110:762-766 (Pubitemid 28194024)
67. Pure E., Inaba K., Crowley M.T., Tardelli L., Witmer-Pack M.D., Ruberti G., et al. Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain. J Exp Med 1990; 172:1459-1469 (Pubitemid 20366222)
68. Caux C., Massacrier C., Vanbervliet B., Dubois B., Durand I., Cella M., et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997; 90:1458-1470 (Pubitemid 27355417)
69. Mizuno K., Okamoto H., Horio T. Ultraviolet B radiation suppresses endocytosis, subsequent maturation, and migration activity of langerhans cell-like dendritic cells. J Invest Dermatol 2004; 122:300-306 (Pubitemid 38281048)
70. Mommaas A.M., Mulder A.A., Jordens R., Out C., Tan M.C., Cresswell P., et al. Human epidermal Langerhans cells lack functional mannose receptors and a fully developed endosomal/lysosomal compartment for loading of HLA class II molecules. Eur J Immunol 1999; 29:571-580 (Pubitemid 29078518)
71. Schaller M., Wurm R., Korting H.C. Direct evidence for uptake of intact liposomes encapsulating silver sulfadiazine by cultured human keratinocytes based on combined transmission electron microscopy and X-ray microanalysis. Antimicrob Agents Chemother 1997; 41:717-719 (Pubitemid 27098434)
72. Abadie V., Bonduelle O., Duffy D., Parizot C., Verrier B., Combadiere B. Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice. PLoS One 2009; 4:e8159.
73. Martinon F., Mayor A., Tschopp J. The inflammasomes: Guardians of the body. Annu Rev Immunol 2009; 27:229-265
74. Cumberbatch M., Dearman R.J., Kimber I. Constitutive and inducible expression of interleukin-6 by Langerhans cells and lymph node dendritic cells. Immunology 1996; 87:513-518 (Pubitemid 26116461)
75. Cumberbatch M., Dearman R.J., Kimber I. Langerhans cells require signals from both tumour necrosis factor alpha and interleukin 1 beta for migration. Adv Exp Med Biol 1997; 417:125-128
76. Cumberbatch M., Dearman R.J., Kimber I. Langerhans cell migration in mice requires intact type I interleukin 1 receptor (IL-1RI) function. Arch Dermatol Res 1999; 291:357-361 (Pubitemid 29281326)
77. Cumberbatch M., Fielding I., Kimber I. Epidermal Langerhans cell migration: Signals and mechanisms. Adv Exp Med Biol 1995; 378:173-175
78. Van der Aar A.M., Sylva-Steenland R.M., Bos J.D., Kapsenberg M.L., De Jong E.C., Teunissen M.B. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol 2007; 178:1986-1990 (Pubitemid 46233394)
79. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811. (Pubitemid 30365397)
80. Gunn M.D., Kyuwa S., Tam C., Kakiuchi T., Matsuzawa A., Williams L.T., et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999; 189:451-460 (Pubitemid 29187367)
81. Randolph G.J., Sanchez-Schmitz G., Angeli V. Factors and signals that govern the migration of dendritic cells via lymphatics: Recent advances. Springer Semin Immunopathol 2005; 26:273-287
82. Geissmann F., Revy P., Regnault A., Lepelletier Y., Dy M., Brousse N., et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999; 162:4567-4575 (Pubitemid 29314856)
83. Ioffreda M.D., Whitaker D., Murphy G.F. Mast cell degranulation upregulates alpha 6 integrins on epidermal Langerhans cells. J Invest Dermatol 1993; 101:150-154 (Pubitemid 23218690)
84. Ouwehand K., Santegoets S.J., Bruynzeel D.P., Scheper R.J., De Gruijl T.D., Gibbs S. CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis. Eur J Immunol 2008; 38:3050-3059
85. Villablanca E.J., Mora J.R. A two-step model for Langerhans cell migration to skin-draining LN. Eur J Immunol 2008; 38:2975-2980
86. Ratzinger G., Stoitzner P., Ebner S., Lutz M.B., Layton G.T., Rainer C., et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 2002; 168:4361-4371 (Pubitemid 34441336)
87. Johnson L.A., Clasper S., Holt A.P., Lalor P.F., Baban D., Jackson D.G. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med 2006; 203:2763-2777 (Pubitemid 44833351)
88. Xu H., Guan H., Zu G., Bullard D., Hanson J., Slater M., et al. The role of ICAM-1 molecule in the migration of Langerhans cells in the skin and regional lymph node. Eur J Immunol 2001; 31:3085-3093 (Pubitemid 32994560)
89. Nakano H., Yanagita M., Gunn M.D. CD11c(+)B220(+) Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001; 194:1171-1178 (Pubitemid 32995786)
90. Randolph G.J., Inaba K., Robbiani D.F., Steinman R.M., Muller W.A. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999; 11:753-761 (Pubitemid 30030714)
91. Abadie V., Badell E., Douillard P., Ensergueix D., Leenen P.J., Tanguy M., et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 2005; 106:1843-1850 (Pubitemid 41208603)
92. Sixt M., Kanazawa N., Selg M., Samson T., Roos G., Reinhardt D.P., et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 2005; 22:19-29. (Pubitemid 40143448)
93. Itano A.A., Jenkins M.K. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 2003; 4:733-739 (Pubitemid 36986756)
94. Stoitzner P., Sparber F., Tripp C.H. Langerhans cells as targets for immunotherapy against skin cancer. Immunol Cell Biol 2010; 88:431-437
95. Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-111 (Pubitemid 46196991)
96. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-89 (Pubitemid 28150594)
97. Segura E., Villadangos J.A. Antigen presentation by dendritic cells in vivo. Curr Opin Immunol 2009; 21:105-110
98. Allenspach E.J., Lemos M.P., Porrett P.M., Turka L.A., Laufer T.M. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity 2008; 29:795-806.
99. Prlic M., Williams M.A., Bevan M.J. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr Opin Immunol 2007; 19:315-319 (Pubitemid 46687015)
100. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: Implications for vaccine development. Nat Rev Immunol 2002; 2:251-262 (Pubitemid 37323225)
101. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8:275-283 (Pubitemid 28188888)
102. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 2008; 8:247-258 (Pubitemid 351432801)
103. Badovinac V.P., Porter B.B., Harty J.T. Programmed contraction of CD8(+) T cells after infection. Nat Immunol 2002; 3:619-626 (Pubitemid 34752470)
104. Seder R.A., Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003; 4:835-842 (Pubitemid 37098653)
105. Williams M.A., Tyznik A.J., Bevan M.J. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006; 441:890-893
106. Sun J.C., Williams M.A., Bevan M.J. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 2004; 5:927-933 (Pubitemid 39276237)
107. Boissonnas A., Combadiere C., Lavergne E., Maho M., Blanc C., Debre P., et al. Antigen distribution drives programmed antitumor CD8 cell migration and determines its efficiency. J Immunol 2004; 173:222-229 (Pubitemid 38797345)
108. Wakim L.M., Waithman J., Van Rooijen N., Heath W.R., Carbone F.R. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 2008; 319:198-202.
109. Gourley T.S., Wherry E.J., Masopust D., Ahmed R. Generation and maintenance of immunological memory. Semin Immunol 2004; 16:323-333 (Pubitemid 39451802)
110. Ratzinger G., Baggers J., De Cos M.A., Yuan J., Dao T., Reagan J.L., et al. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol 2004; 173:2780-2791 (Pubitemid 39063140)
111. Luft T., Jefford M., Luetjens P., Hochrein H., Masterman K.A., Maliszewski C., et al. IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): A mechanism for T cell-independent DC activation. J Immunol 2002; 168:713-722 (Pubitemid 34049572)
112. Schluns K.S., Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003; 3:269-279 (Pubitemid 37328680)
113. Combadiere B., Siberil S., Duffy D. Keeping the memory of influenza viruses. Pathol Biol (Paris) 2010; 58:e79-e86
114. Vien N.C., Feroldi E., Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 2008; 102:294-296
115. Micozkadioglu H., Zumrutdal A., Torun D., Sezer S., Ozdemir F.N., Haberal M. Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Ren Fail 2007; 29:285-288 (Pubitemid 46752340)
116. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
117. Kim Y.C., Quan F.S., Yoo D.G., Compans R.W., Kang S.M., Prausnitz M.R. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009; 27:6932-6938
118. Quan F.S., Kim Y.C., Compans R.W., Prausnitz M.R., Kang SM. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J Control Release 2010.
119. Quan F.S., Kim Y.C., Vunnava A., Yoo D.G., Song J.M., Prausnitz M.R., et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol 2010; 84:7760-7769
120. Purdon C.H., Azzi C.G., Zhang J., Smith E.W., Maibach H.I. Penetration enhancement of transdermal delivery - current permutations and limitations. Crit Rev Ther Drug Carrier Syst 2004; 21:97-132. (Pubitemid 41647584)
121. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 2007; 370:580-589 (Pubitemid 47247854)
122. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-459
123. Glenn G.M., Scharton-Kersten T., Vassell R., Mallett C.P., Hale T.L., Alving C.R. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 1998; 161:3211-3214
124. Glenn G.M., Scharton-Kersten T., Alving C.R. Advances in vaccine delivery: Transcutaneous immunisation. Expert Opin Investig Drugs 1999; 8:797-805. (Pubitemid 29253494)
125. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin. Nature 1998; 391:851. (Pubitemid 28157653)
126. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: A phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371:2019-2025
127. Beignon A.S., Briand J.P., Rappuoli R., Muller S., Partidos C.D. The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin. Infect Immun 2002; 70:3012-3019 (Pubitemid 34564161)
128. Beignon A.S., Briand J.P., Muller S., Partidos C.D. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology 2001; 102:344-351 (Pubitemid 32281163)
129. Partidos C.D., Beignon A.S., Semetey V., Briand J.P., Muller S. The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine 2001; 19:2708-2715 (Pubitemid 32234293)
130. Beignon A.S., Briand J.P., Muller S., Partidos C.D. Immunization onto bare skin with synthetic peptides: Immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virusspecific CD4+ T cells. Immunology 2002; 105:204-212 (Pubitemid 34146687)
131. Stickings P., Peyre M., Coombes L., Muller S., Rappuoli R., Del Giudice G., et al. Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine. Infect Immun 2008; 76:1766-1773 (Pubitemid 351562022)
132. Johnston L., Mawas F., Tierney R., Qazi O., Fairweather N., Sesardic D. Transcutaneous delivery of tetanus toxin Hc fragment induces superior tetanus toxin neutralizing antibody response compared to tetanus toxoid. Hum Vaccin 2009; 5:230-236
133. Rechtsteiner G., Warger T., Osterloh P., Schild H., Radsak M.P. Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005; 174:2476-2480 (Pubitemid 40279657)
134. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., Berzofsky J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004; 113:998-1007. (Pubitemid 38544121)
135. Stoitzner P., Green L.K., Jung J.Y., Price K.M., Tripp C.H., Malissen B., et al. Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol 2008; 180:1991-1998
136. Combadiere B., Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 2008; 31:293-315. (Pubitemid 351315120)
137. Sabchareon A., Chantavanich P., Pasuralertsakul S., Pojjaroen-Anant C., Prarinyanupharb V., Attanath P., et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998; 17:1001-1007 (Pubitemid 28549419)
138. Egemen A., Aksit S., Kurugol Z., Erensoy S., Bilgic A., Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: A comparison of immunogenicity in infants and preschool children. Vaccine 1998; 16:1511-1515 (Pubitemid 28370049)
139. Henderson E.A., Louie T.J., Ramotar K., Ledgerwood D., Hope K.M., Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000; 21:264-269
140. Propst T., Propst A., Lhotta K., Vogel W., Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32:1041-1045 (Pubitemid 28551169)
141. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-2301 (Pubitemid 39552745)
142. Belshe R.B. The burden of influenza and strategies for prevention. Manag Care 2007; 16:2-6; discussion 17-9.
143. Arnou R., Icardi G., De Decker M., Ambrozaitis A., Kazek M.P., Weber F., et al. Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine 2009; 27:7304-7312
144. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nat Med 2000; 6:1403-1406 (Pubitemid 32001027)
145. Frech S.A., Kenney R.T., Spyr C.A., Lazar H., Viret J.F., Herzog C., et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005; 23:946-950 (Pubitemid 39643184)
146. Drape R.J., Macklin M.D., Barr L.J., Jones S., Haynes J.R., Dean H.J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24:4475-4481 (Pubitemid 43776768)
147. Yagi H., Hashizume H., Horibe T., Yoshinari Y., Hata M., Ohshima A., et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 2006; 66:10136-10144 (Pubitemid 44672068)
148. Glenn G.M., Villar C.P., Flyer D.C., Bourgeois A.L., McKenzie R., Lavker R.M., et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: Use of skin pretreatment to disrupt the stratum corneum. Infect Immun 2007; 75:2163-2170 (Pubitemid 46744302)
149. Glenn G.M., Flyer D.C., Ellingsworth L.R., Frech S.A., Frerichs D.M., Seid R.C., et al. Transcutaneous immunization with heat-labile enterotoxin: Development of a needle-free vaccine patch. Expert Rev Vaccines 2007; 6:809-819 (Pubitemid 47607855)
150. Etchart N., Hennino A., Friede M., Dahel K., Dupouy M., Goujon-Henry C., et al. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 2007; 25:6891-6899 (Pubitemid 47391105)
151. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc Natl Acad Sci U S A 2000; 97:371-376 (Pubitemid 30055838)
152. El-Ghorr A.A., Williams R.M., Heap C., Norval M. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice. FEMS Immunol Med Microbiol 2000; 29:255-261
153. Shi Z., Zeng M., Yang G., Siegel F., Cain L.J., Van Kampen K.R., et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 2001; 75:11474-11482 (Pubitemid 33063239)
154. Eyles J.E., Elvin S.J., Westwood A., Lebutt C.S., Alpar H.O., Somavarapu S., et al. Immunisation against plague by transcutaneous and intradermal application of subunit antigens. Vaccine 2004; 22:4365-4373 (Pubitemid 39330362)
155. Skountzou I., Quan F.S., Jacob J., Compans R.W., Kang S.M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 2006; 24:6110-6119 (Pubitemid 44175614)
156. Hickey D.K., Aldwell F.E., Beagley K.W. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections. Vaccine 2009; 27:6217-6225